LivaNova PLC
LIVN
株式のランク
#3794
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
株価
$80.23
時価総額
$4.41B
変化（1日）
0.66%
変化（1年）
46.65%
国
GB
取引 LivaNova PLC (LIVN)
カテゴリー
Healthcare
LivaNova PLC（LIVN）の利益
Jun 2026 時点の利益 TTM: $106.69M
LivaNova PLC の最新の財務報告によると、同社の現在の利益は $106.69M です。2023 年には $-81.33M の利益を上げ、これは 2022 年の利益 $-75.20M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
LivaNova PLC の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $106.69M | 20.81% |
| 2024 | $88.31M | -208.58% |
| 2023 | $-81.33M | 8.16% |
| 2022 | $-75.20M | -39.66% |
| 2021 | $-124.62M | -64.22% |
| 2020 | $-348.29M | 172.89% |
| 2019 | $-127.63M | -48.41% |
| 2018 | $-247.40M | -304.29% |
| 2017 | $121.10M | -466.97% |
| 2016 | $-33.00M | -136.96% |
| 2015 | $89.29M | 11.79% |
| 2014 | $79.88M | 6.12% |
| 2013 | $75.27M | 24.58% |
| 2012 | $60.42M | 24.16% |
| 2011 | $48.66M | 26.44% |
| 2010 | $38.49M | 40.21% |
| 2009 | $27.45M | -358.97% |
| 2008 | $-10.60M | -79.26% |
| 2007 | $-51.10M | -13.34% |
| 2006 | $-58.97M | 383.67% |
| 2005 | $-12.19M | -274.42% |
| 2004 | $6.99M | 31.53% |
| 2003 | $5.31M | -119.60% |
| 2002 | $-27.12M | 412.06% |
| 2000 | $-5.30M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.51B | 6,940.15% |
US
|
|
| $5.56B | 5,114.27% |
IE
|
|
| $5.15B | 4,725.28% |
US
|
|
| $3.86B | 3,518.96% |
US
|
|
| - | - |
DE
|
